[Advances in continuous glucose monitoring: evidence of a new generation technology]

Continuous glucose monitoring (CGM) provides comprehensive and dynamic information to guide the management of diabetes mellitus (DM). This paper summarizes the evidence and implications of the use of the new CGM system, FreeStyle Libre 2 (FSL2). A global review of the literature on the use of FSL2 in people with DM was performed. All types of studies were included. The evidence is presented qualitatively together with expert clinical opinion. FSL2 is an integrated CGM system with real-time glucose readings (no scanning required) and customizable alarms. In studies of subjects aged 2 years and older with DM1 or DM2, the overall mean absolute relative difference for FSL2 was 8.2%, with a high degree of clinical accuracy. Compared to blood monitoring in DM1, studies show higher time within range, lower time below range and lower time above range at 4, 8 and 12 weeks of FSL2 use. These results were confirmed in observational studies in DM, where the majority of FSL2 users reported greater satisfaction with treatment and a significant improvement in quality of life. In concluded, Including the FSL2 system in the management of people with DM would also reduce the risks associated with DM complications, improving the prognosis of this population and allowing for the appropriate use of healthcare resources.